×

VeriTeQ Corporation and Establishment Labs to Host Physician Conference in Europe Based on Demand for Motiva Breast Implants With Q Inside Safety Technology

DELRAY BEACH, Fla., Oct. 15, 2014 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ" or "Company") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that the Company and its breast implant customer, Establishment Labs, S.A., ("EL") are hosting a physician conference in Salzburg, Austria on October 16, 2014, based on demand for EL's Motiva Implant Matrix® breast implants with VeriTeQ's Q Inside Safety Technology™.

As of mid-September, more than 1,000 women in Europe, Latin America and Asia have now received Motiva Implant Matrix® breast implants with Q Inside Safety Technology™. EL's Motiva Implant Matrix® Ergonomix™, VelvetSurface® PLUS, and SilkSurface® PLUS, all with VeriTeQ's Q Inside Safety Technology™, have received CE Mark approval.

VeriTeQ's FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event.

"In conjunction with VeriTeQ, we have advanced Motiva breast implant technology to the 21st century," said EL's Chief Executive Officer Juan Jose Chacon-Quiros. "Patients and physicians are now able to choose our innovative products for enhanced safety and satisfaction."

The educational conference for plastic, aesthetic and reconstructive surgeons is being held at the Kavalierhaus Klessheim in Salzburg, Austria.

About VeriTeQ

VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.

About EL

Establishment Labs is a privately held, global breast, body and facial aesthetic company with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com.

Statements in this press release about our future expectations, including the likelihood that Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event; constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ's ability to raise capital; VeriTeQ's ability to successfully commercialize its Q Inside Safety Technology; as well as other risks. Additional information about these and other factors may be described in VeriTeQ's Form 10-K, filed on April 15, 2014, and Forms 10-Q, filed on August 20, 2014, May 14, 2014, and November 14, 2013, and future filings with the Securities and Exchange Commission The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: VeriTeQ Allison Tomek, 561-846-7003 atomek@veriteqcorp.com

Source:VeriTeQ Corporation